{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:14:41Z","timestamp":1783710881073,"version":"3.55.0"},"reference-count":85,"publisher":"Xia & He Publishing","issue":"4","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.xiahepublishing.com"],"crossmark-restriction":false},"short-container-title":["J Clin Transl Hepatol"],"published-print":{"date-parts":[[2022,8,28]]},"DOI":"10.14218\/jcth.2021.00368","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T01:49:13Z","timestamp":1641260953000},"page":"748-756","update-policy":"https:\/\/doi.org\/10.14218\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment"],"prefix":"10.14218","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-7021","authenticated-orcid":false,"given":"Rongzhi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9855-6730","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nature Med"},{"issue":"18","key":"key20220104014845_JCTH-D-21-00368-b2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S2468-1253(20)30057-1","article-title":"Liver injury in COVID-19: management and challenges","volume":"5","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/liv.14435","article-title":"Liver injury during highly pathogenic human coronavirus infections","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int"},{"issue":"9","key":"key20220104014845_JCTH-D-21-00368-b5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41575-020-0328-2","article-title":"COVID-19 and the liver-related deaths to come","volume":"17","author":"Pawlotsky","year":"2020","journal-title":"Nature Rev Gastroenterol Hepatol"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40264-020-00954-z","article-title":"Drug-induced liver injury and COVID-19 infection: The rules remain the same","volume":"43","author":"Olry","year":"2020","journal-title":"Drug Saf"},{"key":"key20220104014845_JCTH-D-21-00368-b7","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0000000000002021","article-title":"The liver in COVID-19: prevalence, patterns, predictors, and impact on outcomes of liver test abnormalities","author":"Goel","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b8","doi-asserted-by":"crossref","first-page":"100169","DOI":"10.1016\/j.jhepr.2020.100169","article-title":"Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic","volume":"2","author":"Boettler","year":"2020","journal-title":"JHEP Rep"},{"issue":"9","key":"key20220104014845_JCTH-D-21-00368-b9","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/liv.14455","article-title":"Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b10","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","article-title":"COVID-19: Abnormal liver function tests","volume":"73","author":"Cai","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b11","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/all.14309","article-title":"COVID-19 in a designated infectious diseases hospital outside Hubei Province, China","volume":"75","author":"Cai","year":"2020","journal-title":"Allergy"},{"issue":"12","key":"key20220104014845_JCTH-D-21-00368-b12","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/hep4.1592","article-title":"Clinical features of patients with COVID-19 with nonalcoholic fatty liver disease","volume":"4","author":"Huang","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/2050640620924157","article-title":"Liver injury in COVID-19: The current evidence","volume":"8","author":"Alqahtani","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"8","key":"key20220104014845_JCTH-D-21-00368-b14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4254\/wjh.v12.i8.413","article-title":"Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?","volume":"12","author":"Brito","year":"2020","journal-title":"World J Hepatol"},{"issue":"18","key":"key20220104014845_JCTH-D-21-00368-b15","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cpt.1866","article-title":"Incidence of adverse drug reactions in COVID-19 patients in China: An active monitoring study by hospital pharmacovigilance system","volume":"108","author":"Sun","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/apt.15916","article-title":"Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19","volume":"52","author":"Kulkarni","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00296-009-1237-4","article-title":"Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis","volume":"31","author":"Her","year":"2011","journal-title":"Rheumatol Int"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","article-title":"Clinical features of COVID-19-related liver functional abnormality","volume":"18","author":"Fan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"key20220104014845_JCTH-D-21-00368-b20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","article-title":"Case report: Hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19","volume":"102","author":"Falc\u00e3o","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"19","key":"key20220104014845_JCTH-D-21-00368-b21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19-Final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"key20220104014845_JCTH-D-21-00368-b22","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"key20220104014845_JCTH-D-21-00368-b23","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"24","key":"key20220104014845_JCTH-D-21-00368-b24","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of Remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"10236","key":"key20220104014845_JCTH-D-21-00368-b25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"key20220104014845_JCTH-D-21-00368-b26","unstructured":"Fujifilm Pharmaceuticals U.S.A., Inc. Study of the use of Favipiravir in hospitalized subjects with COVID-19. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358549"},{"issue":"10","key":"key20220104014845_JCTH-D-21-00368-b27","first-page":"1192","article-title":"Experimental treatment with Favipiravir for COVID-19: An open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b28","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.1016\/j.jhepr.2020.100113","article-title":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper","volume":"2","author":"Boettler","year":"2020","journal-title":"JHEP Rep"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jvh.13410","article-title":"Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy","volume":"28","author":"Rodr\u00edguez-Tajes","year":"2021","journal-title":"J Viral Hepat"},{"issue":"11","key":"key20220104014845_JCTH-D-21-00368-b31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/hepr.13553","article-title":"Longitudinal changes of liver function and hepatitis B reactivation in COVID-19 patients with pre-existing chronic hepatitis B virus infection","volume":"50","author":"Liu","year":"2020","journal-title":"Hepatol Res"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13098-020-00583-7","article-title":"Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes","volume":"12","author":"Alessi","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-020-00333-0","article-title":"Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment","volume":"21","author":"Marra","year":"2021","journal-title":"Drugs R D"},{"issue":"17","key":"key20220104014845_JCTH-D-21-00368-b34","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20220104014845_JCTH-D-21-00368-b35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40264-021-01089-5","article-title":"NSAIDs and COVID-19: A systematic review and meta-analysis","volume":"44","author":"Moore","year":"2021","journal-title":"Drug Saf"},{"issue":"2","key":"key20220104014845_JCTH-D-21-00368-b36","first-page":"131","article-title":"Acetaminophen-induced hepatotoxicity: a comprehensive update","volume":"4","author":"Yoon","year":"2016","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cld.2013.07.005","article-title":"Acetaminophen-related hepatotoxicity","volume":"17","author":"Bunchorntavakul","year":"2013","journal-title":"Clin Liver Dis"},{"key":"key20220104014845_JCTH-D-21-00368-b38","article-title":"Truven Health Analytics Inc. and Micromedex Inc., Micromedex gateway 2011, Truven Health Analytics"},{"key":"key20220104014845_JCTH-D-21-00368-b39","article-title":"Plaquenil Hydroxychloroquine Sulfate Tablets US Prescribing Information 2017"},{"key":"key20220104014845_JCTH-D-21-00368-b40","article-title":"Plaquenil-Hydroxychloroquine sulfate 200mg Film-coated Tablets, Summary of Product Characteristics. Zentiva; 2020"},{"key":"key20220104014845_JCTH-D-21-00368-b41","article-title":"Therapeutic drugs. 2nd ed. Churchill Livingstone, London; 1998","author":"Dollery"},{"issue":"1A","key":"key20220104014845_JCTH-D-21-00368-b42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am J Med"},{"issue":"6","key":"key20220104014845_JCTH-D-21-00368-b43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"key20220104014845_JCTH-D-21-00368-b44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jac\/dkg319","article-title":"Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant plasmodium falciparum, in agreement with its physicochemical properties","volume":"52","author":"Warhurst","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"key20220104014845_JCTH-D-21-00368-b45","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","article-title":"Synthesis and antiviral activity of a series of 1\u2032-substituted 4-aza-7,9-dideazaadenosine C-nucleosides","volume":"22","author":"Cho","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b46","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1- ftriazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J Med Chem"},{"issue":"396","key":"key20220104014845_JCTH-D-21-00368-b47","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"issue":"12","key":"key20220104014845_JCTH-D-21-00368-b48","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"10","key":"key20220104014845_JCTH-D-21-00368-b50","doi-asserted-by":"crossref","first-page":"e239210","DOI":"10.1136\/bcr-2020-239210","article-title":"Use of Remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection","volume":"13","author":"Sabers","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b51","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/cid\/ciaa883","article-title":"Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of Remdesivir with p-Glycoprotein inhibitors","volume":"72","author":"Leegwater","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"key20220104014845_JCTH-D-21-00368-b52","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/phar.2464","article-title":"Acetylcysteine for the treatment of suspected Remdesivir-associated acute liver failure in COVID-19: A case series","volume":"40","author":"Carothers","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b53","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b54","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b55","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"key20220104014845_JCTH-D-21-00368-b57","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (Favipiravir) and Ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"9","key":"key20220104014845_JCTH-D-21-00368-b59","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key20220104014845_JCTH-D-21-00368-b60","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci Rep"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b61","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","article-title":"Favipiravir (T-705) inhibits in vitro norovirus replication","volume":"424","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"10229","key":"key20220104014845_JCTH-D-21-00368-b63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b64","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: A single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"issue":"24","key":"key20220104014845_JCTH-D-21-00368-b65","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"key20220104014845_JCTH-D-21-00368-b66","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/liv.14516","article-title":"First case of drug-induced liver injury associated with the use of Tocilizumab in a patient with COVID-19","volume":"40","author":"Muhovi\u0107","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"key20220104014845_JCTH-D-21-00368-b67","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course Tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol Rev"},{"key":"key20220104014845_JCTH-D-21-00368-b69","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1476-5381.2011.01394.x","article-title":"Importance of the multidrug and toxin extrusion MATE\/SLC47A family to pharmacokinetics, pharmacodynamics\/toxicodynamics and pharmacogenomics","volume":"164","author":"Yonezawa","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b70","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1038\/s41598-021-97160-3","article-title":"Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics","volume":"11","author":"Ambrus","year":"2021","journal-title":"Sci Rep"},{"key":"key20220104014845_JCTH-D-21-00368-b71","unstructured":"Aspen. Dexamethasone 2mg tablets, Summary of Product Characteristics; Accessed 10 Nov 2020. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5411\/smpc"},{"issue":"5","key":"key20220104014845_JCTH-D-21-00368-b72","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.3892\/etm.2016.3720","article-title":"Evaluation of the efficacy of steroid therapy on acute liver failure","volume":"12","author":"Zhao","year":"2016","journal-title":"Exp Ther Med"},{"issue":"9902","key":"key20220104014845_JCTH-D-21-00368-b73","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0140-6736(12)62163-1","article-title":"Autoimmune hepatitis","volume":"382","author":"Heneghan","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0960-0760(97)00038-1","article-title":"Dexamethasone metabolism in vitro: species differences","volume":"62","author":"Tomlinson","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"key20220104014845_JCTH-D-21-00368-b75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajg.2020.04.019","article-title":"Liver transplantation in the era of COVID-19","volume":"21","author":"El Kassas","year":"2020","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b76","first-page":"e17","article-title":"Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor","volume":"8","author":"Rismanbaf","year":"2020","journal-title":"Arch Acad Emerg Med"},{"issue":"2","key":"key20220104014845_JCTH-D-21-00368-b77","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatol"},{"issue":"6","key":"key20220104014845_JCTH-D-21-00368-b78","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"key20220104014845_JCTH-D-21-00368-b79","doi-asserted-by":"crossref","first-page":"e00162","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"13","key":"key20220104014845_JCTH-D-21-00368-b80","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","article-title":"Remdesivir: first approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"key20220104014845_JCTH-D-21-00368-b81","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/1060028020925558","article-title":"Emergency authorization of chloroquine and hydroxychloroquine for treatment of COVID-19","volume":"54","author":"Piszczatoski","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"3","key":"key20220104014845_JCTH-D-21-00368-b82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-020-03017-5","article-title":"Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies","volume":"77","author":"Zhao","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"key20220104014845_JCTH-D-21-00368-b83","first-page":"465","article-title":"Lopinavir-ritonavir in severe COVID-19","volume":"26","author":"Stower","year":"2020","journal-title":"Nat Med"},{"issue":"Suppl E","key":"key20220104014845_JCTH-D-21-00368-b84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31","author":"Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"key20220104014845_JCTH-D-21-00368-b85","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:21:04Z","timestamp":1783707664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":85,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,5,11]]},"published-print":{"date-parts":[[2022,8,28]]}},"alternative-id":["10.14218\/JCTH.2021.00368"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2021.00368","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}